L&C BIO
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
L&C BIO makes human tissue-derived products, biological materials processed from donated human tissue and used in surgical procedures such as bone grafts and wound repair.
Its products are supplied to hospitals and surgical teams. The company is listed on KOSDAQ, South Korea's tech and small-cap exchange. The filing text does not clearly specify a single dominant product line or structural business model beyond its tissue-based medical product portfolio.
Summary is AI-generated and may contain errors · figures from DART filings
L&C BIO in five facts
What does L&C BIO do?
L&C BIO makes human tissue-derived products, biological materials processed from donated human tissue and used in surgical procedures such as bone grafts and wound repair.
Where is L&C BIO listed and in which sector?
L&C BIO (Korean name: 엘앤씨바이오) trades under KRX code 290650 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is L&C BIO?
Its market capitalisation was US$1.3B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were L&C BIO's latest annual revenue and operating profit?
For fiscal year 2025, L&C BIO reported revenue of US$64.5M, operating profit of US$3.3M and a net loss of US$104.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 18.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · Oct 16
- Rights offering: final issue price setCapital raise · Oct 12
- [Amended] ProspectusOct 12
- [Terms finalized] Securities registration statement (equity)Oct 12
- [Amended] Material event report (paid-in and bonus issue)
L&C BIO updated the terms of a new share issuance to raise US$108M, about 9.5% of its market value.
Capital raise · Oct 12 · 3 versions - Report on securities held by executives/major shareholdersSep 30
- Report on large shareholdings (5% rule) (standard)Sep 30
- Report on securities held by executives/major shareholdersSep 23
- Report on securities held by executives/major shareholdersSep 23
- Report on securities held by executives/major shareholdersSep 23
- Report on securities held by executives/major shareholdersSep 23
- Report on securities held by executives/major shareholdersSep 23
- Report on large shareholdings (5% rule) (standard)Sep 18
- Report on securities held by executives/major shareholdersSep 18
- Report on large shareholdings (5% rule) (abbreviated)Sep 10
- Report on large shareholdings (5% rule) (standard)Sep 9
- Ex-rights (rights offering)
L&C BIO Co., Ltd. (common shares, ticker code A290650) will go ex-rights on 2026-09-03 due to its ongoing rights offering, with a base price of US$38.50.
Capital raise · Sep 2 - Rights offering: round 1 issue price set
L&C BIO Co., Ltd. set the round-1 issue price for its planned rights offering of 3,700,000 registered common shares (par value US$0.37) at US$28.78 per share, calculated as of 2026-09-01, with the final issue price to be announced on 2026-10-12.
Capital raise · Sep 2 - ProspectusSep 2
- [Terms finalized] Securities registration statement (equity)Sep 2
- DisclosureSep 2
- [Amended] Securities registration statement (equity)Aug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
L&C BIO filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$27.5M (+88.4% year on year), operating profit of US$6.08M (from a loss a year earlier) and a net loss of US$19.9M.
Earnings · Aug 11 - Operating results (preliminary) (fair disclosure)
L&C BIO filed provisional (unaudited) separate results for Q2 2026: revenue of US$22.4M (+91.7% year on year), operating profit of US$6.26M (+624.8% year on year) and a net loss of US$19.4M.
Earnings · Aug 11 - Trading suspension (bonus issue)
The exchange suspended trading in L&C BIO's common shares from 15:56 on 2026-07-31 until market close due to a bonus share issue, under KOSDAQ Market Disclosure Regulation Article 37 and its Enforcement Rules Article 18.
Capital raise · Jul 31 - Operating results (preliminary) (fair disclosure)
L&C BIO filed provisional (unaudited) separate results for Q1 2026: revenue of US$16.2M (+63.42% year on year), operating profit of US$4.39M (+546.82% year on year) and net income of US$2.24M (+400.61% year on year).
Earnings · May 11 - Operating results (consolidated) (preliminary) (fair disclosure)
L&C BIO filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$20.5M (+70.61% year on year), operating profit of US$4.07M (from a loss a year earlier) and net income of US$1.85M (from a loss a year earlier).
Earnings · May 11 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
L&C BIO reported consolidated results for FY2025: revenue of US$59.7M (+18.5% year on year), operating profit of US$2.96M (+66.8% year on year) and a net loss of US$90.1M (from a profit a year earlier).
Earnings · Feb 27 - [Amended] Material event report (rights offering)Capital raise · Jan 9